Addressing Key Mechanisms of Tumor Drug Resistance
|
|
- Dwight Merritt
- 6 years ago
- Views:
Transcription
1 Addressing Key Mechanisms of Tumor Drug Resistance April 2018 Kinase switch control inhibitors for tumortargeted and immune-targeted cancer therapies
2 Disclaimer This presentation has been prepared by Deciphera Pharmaceuticals, Inc. for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation Deciphera Pharmaceuticals, Inc. or any director, employee, agent, or adviser of Deciphera Pharmaceuticals, Inc. This presentation does not purport to be all-inclusive or to contain all of the information you may desire. Certain information contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and Deciphera Pharmaceuticals, Inc.'s own internal estimates and research. While Deciphera Pharmaceuticals, Inc. believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. While Deciphera Pharmaceuticals, Inc. believes its internal research is reliable, such research has not been verified by any independent source. Forward-Looking Statements This presentation may contain forward-looking statements that are based on our current expectations, estimates and projections about our industry as well as management's beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks, "estimates," "may," "will," and variations of these words or similar expressions are intended to identify forward-looking statements. These statements include statements regarding our business strategy, prospective products, clinical trial results, product approvals and regulatory pathways, timing and likelihood of success, plans and objectives of management for future operations, future results of anticipated products, and the market opportunity for our drug candidates, and speak only at the time this presentation was prepared. Such statements are based upon the information available to us now and are subject to change. We will not necessarily inform you of such changes. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Therefore actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various factors. Factors which could cause actual results to differ materially from those in the forward-looking statements include, among others, our history of significant losses since inception, our ability to obtain necessary capital when needed on acceptable terms, the results from ongoing or future clinical and nonclinical trials, our ability to obtain regulatory approval or clearance of our drug candidates, competition from other products or procedures, our reliance on third-parties to conduct our clinical and non-clinical trials, our reliance on singlesource third-party suppliers to manufacture clinical, non-clinical and any future commercial supplies of our drug candidates and our ability to obtain, maintain and enforce our intellectual property rights for our drug candidates. This presentation may contain trade names, trademarks or service marks of other companies. Deciphera does not intend the use or display of other parties trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of, these other parties. 2
3 Corporate Summary Well established drug class with significant growth potential Differentiated approach to kinase inhibition Wholly-owned pipeline with three clinical stage assets Kinase Inhibitors: 39 FDA-approved Drugs but Significant Opportunities Remain Drug resistance mutations limit rate and duration of response Low potency and selectivity cause poor tolerability Approved drugs target less than 10% of the 500+ known human kinases Proprietary Kinase Switch Control Inhibitor Platform Broad activity against disease-initiating and drug-resistant mutant kinases Kinase-selective and spectrum-selective profiles Drug discovery engine that fuels long-term growth Strong Pipeline of Tumor-Targeted and Immunokinase Programs DCC-2618: Broad spectrum KIT and PDGFRα inhibitor in first pivotal Phase 3 trial Rebastinib: Highly potent and selective TIE2 inhibitor DCC-3014: Highly selective and potent CSF1R inhibitor 3
4 Experienced Management Team Michael D. Taylor, PhD CEO Daniel L. Flynn, PhD CSO/Founder Oliver Rosen, MD CMO Tucker Kelly, JD CFO Christopher J. Morl, MBA CBO 4
5 Strong Clinical-Stage Small Molecule Pipeline Tumor-Targeted Programs and Indications Pre-Clinical Phase 1 Phase 2 Phase 3 Global Rights Immunokinase Programs and Indications Pre-Clinical Phase 1 Phase 2 Phase 3 Global Rights DCC-2618 KIT & PDGFRα GIST 1 Rebastinib TIE2 Breast Cancer + Chemotherapy 2 PDGFRα GBM & Glioma TIE2 Checkpoint Inhibitor Combination KIT (D816V) Advanced Systemic Mastocytosis DCC-3014 CSF1R Solid Tumors & Hematological Malignancies KIT & PDGFRα Other Cancers CSF1R Checkpoint Inhibitor Combination Undisclosed Cancer Metabolism Undisclosed Immunokinase Note: (1) Phase 3 Pivotal Study in 4 th line & 4 th line+ patients. 5 Note: (2) Investigator initiated and sponsored research.
6 Our Proprietary Kinase Switch Control Platform Kinase Switched Off Kinase Switched On Deciphera Switch Control Switch pocket Activation switch Off Activation switch On Advantages of Switch Control Inhibitors Switch control inhibitor embeds deeply into switch pocket Inhibits switch activation Tumor-Targeted Programs Immunokinase Programs (Macrophage Checkpoints) Broader Activity Enhanced Durability Engineered Profiles Superior Binding Inhibit wild-type and many or all mutant forms of targeted kinases Resilient to gain-of-function mutations and drug resistance Highly selective or target multiple kinases at desired potency More potent and more durable; resilient to ATP concentration 6
7 DCC-2618: Broad Spectrum KIT & PDGFRα Inhibitor
8 DCC-2618: A Potent, Broad Spectrum KIT and PDGFRα Inhibitor DCC-2618 Summary Highly potent small molecule KIT and PDGFRα inhibitor Designed to inhibit the full spectrum of known KIT and PDGFRα mutations Fast-to-Market strategy with significant opportunity for label expansion Phase 3 pivotal trial in 4 th Line and 4 th Line+ GIST initiated January 2018 Phase 3 pivotal trial in 2 nd Line GIST planned for 2H:18 Phase 1 expansion study ongoing Clinical proof-of-concept in GIST 91% Disease Control by Best Response (PR & SD) by RECIST 100 mg daily Disease Control Rate 100 mg daily: 76% (12 weeks) and 57% (24 weeks) Favorable tolerability profile Doses up to 400 mg total per day with no MTD 150 mg QD selected for expansion and pivotal, registration Phase 3 trials IP: Composition and method of use (2032) Preclinical Profile 8
9 Pivotal Phase 3 Study in 4 th Line+ GIST Initiated Jan 2018 (1) Global Trial (n=120) 3 prior lines of therapy (1) Randomized 2:1 150 mg QD DCC Patients GIST Patients Placebo 40 Patients Primary Endpoint for Approval = Median Progression Free Survival Following progression: (a) placebo patients can crossover to DCC-2618 and (b) DCC-2618 patients can continue on treatment. Note: (1) Phase 3 Pivotal Study in 4 th line & 4 th line+ patients who previously received at least imatinib, sunitinib, and regorafenib. 9
10 GIST: A Polyclonal Disease Driven by KIT and PDGFRα Primary KIT and PDGFRα Mutations in GIST Patients Multiple Secondary KIT Mutations Produce Drug Resistance KIT and PDGFRα Mutations in GIST Wild-type tumors: 15% Primary KIT Mutations Secondary KIT Mutations KIT (75%) PDGFRα (10%) Extracellular domain Transmembrane domain Exon 9 (8%) Exon 11 (65%) Exon 13 (1%) Exon 17 (1%) Exon 12 (2%) Exon 14 (rare) Exon 18 (8%) (Includes D842V) Juxtamembrane domain Tyrosine kinase domain I/ ATP-binding pocket Tyrosine kinase domain I/ ATP-binding pocket Corless; M. Pathology 2014 George; Ther. Adv. in Medical Oncology
11 Multiple Drug-Resistant Secondary Mutations in GIST Drug-Resistant Secondary KIT Mutations in GIST Patients Span Exon Regions Distribution of secondary KIT mutations (n=27) Fletcher; J. Pathol 2008 Switch Pocket Region Switch Region A I H G Y Y K D P V Exon 13 Exon 14 Exon 17 Exon 1 8 ATP binding pocket 42.9% T Kinase activation loop 57.1% Color code for primary mutation D D D N N Y Exon 11 Exon 9 Exon 13 A High Degree of Tumor Mutation Heterogeneity in GIST Patients Number of secondary mutants detected per patient 10 (n=37)* Number of Secondary Mutants per Patient secondary mutations were observed in 35% (13/37) of patients. 54% (13/24) of patients with KIT exon 11, with 1 patient harboring 8. Heinrich, Abstract ASCO 2015 Primary Mutation Status KIT exon 11 KIT other** KIT WT 11 Notes: (*) Number of unique secondary mutants per patient observed across all samples analyzed; (**) Includes exon 9 (n=6), exon 13 (n=1), and exon 17 (n=1).
12 DCC-2618 Broad Coverage of Primary and Secondary Mutations in KIT and PDGFRα DCC-2618 Broadly Inhibits KIT and PDGFRα Mutations In Enzyme Assays DCC-2618 Inhibits Phosphorylation of KIT and PDGFRα in Cellular Assays K inase Inhibition at 1 m M A TP DCC-2618 (Type II) DP-5439 (Type II) Im atinib (Type II) S unitinib b (Type II) Regorafenib (Type II) Midostaurin (Type I) BLU-285 (Type I) IC 50 (nm ) K IT a V654A T670I D816H D816V PDGFRA D842V KIT a V654A T670I D816H D816V PDGFRA D842V K IT a V A T I D816H D V DCC-2618 broadly inhibits KIT mutations in exons 9, 11, 13, 14, 17, 18, and a PDGFRA exon 18 mutant. Other Type II inhibitors do not block KIT exon 17 mutations, including D816V KIT. Type I inhibitors exhibit weak activity for primary KIT mutations in exon 9, exon 11 V560D, and exon 13 K642E and for secondary KIT mutations in exons 13 and 14. PDGFRA D842V KIT a V A T I D H D V P D G F R A D V K IT a V A T I D H D V P D G F R A D V K IT a V A T I D H D V P D G F R A D V K IT a V A T I D H D V a Phosphorylated on the juxtamembrane domain. b Sunitinib is Type I-like but binds to KIT in the inactive Type II conformation. P D G F R A D V Mutation Exon KIT V654A 13 KIT T670I 14 KIT D816H 17 KIT D816V 17 PDGFRA D842V Notes: (A) GIST primary mutations; or imatinib-resistant KIT mutations with (B) exon 9 or (C) exon 11 primary mutations.
13 Approved Therapies for GIST: Clinical Goal is Disease Control First Line Second Line Third Line imatinib (n=147) (Blanke et al. 2008) sunitinib (n=243) (Demetri et al. 2012) regorafenib (n=133) (Demetri et al. 2013) Progression Free Survival 1 (months) Objective Response Rate (%) 68.1% 7.0% 4.5% Stable Disease (%) 15.6% 53.0% 48.1% Disease Control Rate ( DCR ) (%) 83.7% % % 3 No approved therapy for 4 th line patients Notes: (1) Includes progression free survival and time to progression; (2) Time point not disclosed; (3) Time point at 12 weeks. 13
14 DCC-2618 Phase 1 Trial Part 1: Dose Escalation Key Objectives: MTD, recommended Phase 2 dose, safety, tolerability, pharmacokinetics and anti-tumor activity Design: 3+3 design with enrichment of targeted patients Dose Levels: 20, 30, 50, 100, 150, and 200 mg BID; and 100 and 150 mg QD MTD: not determined Part 2: Dose Expansion 6 cohorts enrolling (up to 200 patients) 4 th Line GIST 5 th Line GIST 2 nd 3 rd Line GIST Advanced Malignancies (n=68) Recommended Dose 150 mg QD Phase 1 Trial Enrollment as of January 18, total patients ( mg QD) 142 GIST patients (100 GIST 150 mg QD) Systemic Mastocytosis and Associated Hematological Malignancies Malignant Gliomas Other Solid Tumors 14
15 Broad and Sustained Tumor Control in GIST Patients 91% Disease Control (PR & SD) at Best Response by RECIST at 100 mg Daily Best Response per RECIST KIT & PDGFRα All Doses (n=37) 76% DCR 100 mg Daily (12 Weeks) 57% DCR 100 mg Daily (24 Weeks) Tumor Control per RECIST KIT & PDGFRα 100 mg Daily (n=33) # # # # # # # # # * Notes: (a) Uncleaned EDC data per investigator assessment; (b) Includes only KIT and PDGFRα GIST patients; excludes one SDH GIST patient (c) PD = Progressive disease, SD = Stable disease, PR = Partial response (d) *Indicates a 66% increase in tumor size; (e) # = 150mg QD; (f) per investigator assessment. Notes: (a) Closed circles denote patient on DCC-2618 at time of scan; (b) Open circles denote patient was off DCC-2618 at time of scan; (c) Stars indicate final visit; (d) per investigator assessment. (e) Patient #13 censored (week 24) due to surgery; on study (week 53) as of cut off. 15
16 Clinical Validation of The Broad Spectrum Profile in Liquid Biopsies Reductions in Circulating MAF of Mutations in all Clinical Relevant Exons (n=19) (Note log scale: -1 = 10-fold reduction, -2 = 100-fold reduction) fold + 10 fold # # - 10 fold fold - 1,000 fold 47 Ex 9 Ex 11 Ex 13 Ex 14 Ex 17 Ex 18 KIT mutations across 6 exons (9, 11, 13, 14, 17 & 18) Notes: (a) Patient #3 in first dose cohort; (b) Patient #*34 presented with mixed histology; (c) 47 KIT mutations based on data from 27 patients including 8 with only baseline data. 16
17 Duration of Treatment in Heavily Pretreated GIST Patients (n=57) (a)(b) Median PFS with placebo in 3 rd /4 th line (<1 month) AACR 2018 Update (c) GIST pts 100 mg/d as of 1/18/18 (n=137): 81 of 137 remain on study as of 3/19/18 >6 months on study (n=46) >9 months on study (n=21) >12 months on study (n=10) >15 months on study (n=7) Notes: (a) Tumor response data is based on investigator assessment; (b) Data from presentation at ESMO on September 11, 2017; (c) Data from presentation at AACR on April 15, Weeks on DCC = patients receiving 150mg QD
18 Early Progression Free Survival Data Progression-Free Survival Rate KIT- and PDGFRα-driven GIST Patients 100 mg daily (n=49) vs. < 100 mg daily (n=4) Median PFS with placebo in 3 rd /4 th line (<1 month) Progression-free survival mpfs is 15.2 weeks (CI 4.4 to 24) All patients treated at <100mg daily (n=4) mpfs cannot be determined All patients treated at 100mg daily (n=49) Notes: (a) Circles are patients (potentially >1 at any time point) who had not progressed as of end of treatment/study or last visit date if still on treatment; (b) Data is based on tumor response data investigator assessment. 18
19 Activity in GBM with a Durable Partial Response Society for Neuro-Oncology (November 2017) Baseline Post Cycle 22 Baseline 51.4 mm x 26.8 mm Cycle 23 Day mm x 8.4 mm 1 PR of 4 Evaluable GBM Patients 3 Patients Non-evaluable at Cut-off (1 PD, 2 Active) Stage 4 GBM with PDGFRα, KIT, VEGFR2 6x amp. 94% Tumor Reduction per RANO after 22 Cycles 19
20 Favorable Tolerability Profile Treatment-emergent Adverse Events in (10%) GIST Patients 150 mg QD Phase 1 Dose Escalation (n=68) Well tolerated up to 400 mg per day MTD not reached 3 DLTs: Reversible plasma enzyme elevations: lipase (2) and CPK (1) Deemed not clinically significant 150 mg QD dose for Phase 1 Expansion and 4 th Line GIST Phase 3 Trial GIST 150 mg QD ADVERSE EVENT GRADE GRADE TOTAL 1/2 3/4 (n=100) Alopecia (39%) Fatigue (39%) Myalgia (35%) Constipation (29%) Hand-Foot-Skin reaction (27%) Rash (21%) Lipase increased (20%) Nausea (19%) Decreased appetite (18%) Diarrhea (18%) Hypertension (17%) Abdominal pain (16%) Arthralgia (15%) Weight decreased (13%) Headache (12%) Vomiting (12%) Anemia (11%) Dyspnea (11%) Hypomagnesaemia (11%) Pain in extremity (11%) Dry skin (10%) Muscle spasms (10%) 20
21 Estimated Market Opportunity: US, EU & Japan Incidence Metastatic GIST US EU Japan Total (exc. ROW) KIT-driven 4 th Line 1&2 ~2,100 ~3,300 ~800 ~6,200 KIT-driven 2 nd Line 1&2 ~2,600 ~4,000 ~1,000 ~7,600 PDGFRα-driven 1&2 ~400 ~600 ~160 ~1,160 GBM & Glioma (PDGFRα Amp.) 3&4 ~2,400 ~3,700 ~900 ~7,000 Advanced Systemic Mastocytosis 5 ~1,400 ~2,100 ~500 ~4,000 Estimated Annual Incidence of New Patients by Indication Sources: Internal Deciphera estimates based on applying epidemiology data reported in the following publications to population estimates for US, EU (28) and Japan: 1 Zhao et al. J Gastrointest Oncol 2012;3(3): Metaxas Y, et al. ESMO Open Bastien et al.cancer 2014;121: Schwartzbaum et al. Nature Clinical Practice Neurology Sep 2006 Vol 2 No 9 5 Cohen et al. British Journal of Haematology, 2014, 166,
22 Immunokinase Programs Targeting Macrophage Checkpoints: Rebastinib and DCC-3014
23 Immunokinase Programs: Rebastinib and DCC-3014 Combining T-Cell and Macrophage Checkpoint Inhibitors Targeting T-Cells and Macrophages to Produce Strong Tumor Cell Killing 23
24 Rebastinib: A Highly Potent and Selective TIE2 Inhibitor TIE2 Legend: IC50= 10 nm IC50 = 1 nm Rebastinib Summary Potent, small molecule inhibitor of TIE2 Phase 1 study completed Patients with relapsed/refractory chronic (BCR-ABL+) or AML (FLT3-ITD) MTD determined based on targeting BCR-ABL. 100x more potent inhibitor of TIE2. Lower dosing to be used for future development. Preclinical anti-tumor activity Single agent and I/O or chemo combination TIE2 microenvironment mechanisms Tumor vascularization, dissemination, metastasis, immunotolerance Development Status Ongoing investigator-sponsored chemo combo trial Company sponsored combination trial planned for 2018 IC50 = 0.1 nm IP: Composition (2027) and method of use (2034) Kinome Profile 24 Notes: All kinases within 100-fold of TIE2 IC50 (0.058 nm) are shown. Includes enzyme data at low ATP and 4 mm ATP, and cellular data
25 Rebastinib: Rationale for Use in Combination Therapies Rebastinib Inhibits Growth of Breast Tumors (PyMT) Alone and in Combination With Paclitaxel Rebastinib Inhibits Growth of Breast Tumors (PyMT) Alone and in Combination With PD-1 PyMT Mean Primary Tumor Burden PyMT 3000 Mean Tumor Burden (mg) +/- SE PyM T M ean Prim ary Tum or Burden Days Post Tumor Implant V ehicle Paclitaxel 10 mg/kg Q5Dx5 IV Rebastinib 10 mg/kg BID PO Rebastinib + Paclitaxel Paclitaxel 49% TGI R eb a stin ib 75% TGI Rebastinib plus Paclitaxel 90% TGI Tumor volume (mm 3 ) Day Notes: *TGI normalized to starting tumor size: Paclitaxel (49%TGI*) Rebastinib (75%TGI*); Rebastinib plus Paclitaxel (90%TGI*). Anti-PD1 (RMP1-14) 10 mg/kg IP BIW Rebastinib + Anti-PD1 Vehicle Rebastinib 10 mg/kg PO QD 25
26 DCC-3014: A Highly Selective and Potent CSF1R Inhibitor DCC-3014 Summary Highly selective, potent, small molecule CSF1R inhibitor 100x selectivity over closest kinases Phase 1 study ongoing Up to 55 patients with advanced malignancies (including solid or hematological malignancies where TAMs may be involved) Preclinical anti-tumor activity Single agent and in combination with anti-pd1 CSF1R mechanisms Reverses immunosuppression via depletion of TAMs, increases in cytotoxic T cells and decreases in T reg cells Development Status Phase 1 trial ongoing 4mM ATP Legend: 10 μm 1 μm 100 nm 10 nm 1 nm IP: Composition and method of use (2034) Kinome Profile 26
27 DCC-3014: Rationale for Combination with PD-1 Inhibitors DCC-3014 Inhibits Growth of Colorectal Tumors Alone and in Combination with anti-pd-1 DCC-3014 Reverses Immunosuppression in Colorectal Tumor Model MC-38 Primary Tumor Growth Decrease in ratio of TAMs to CD8 cytotoxic T Cells Increase in ratio of CD8 cytotoxic T Cells to T reg cells Macrophage:CD8+ T cell Ratio MC-38 Syngeneic Model Tumor Flow Cytometry Analysis Ve hicle DCC mg/kg Cytotoxic CD8+ T cell:treg Ratio MC-38 Syngeneic Model Tumor Flow Cytometry Analysis Ve hicle DCC mg/kg 27
28 Upcoming Milestones AACR: Phase 1 Escalation Data 4 th line GIST: Pivotal Phase 3 Initiated 4 th Line GIST: Pivotal Phase 3 Initial Data DCC-2618 Phase 1 Expansion Initiation ASCO: Phase 1 Escalation Data Phase 1 Dose Escalation Completion AACR: Phase 1 Safety/PK Data AACR: Preclinical Data Phase 1 Safety & Efficacy Data Phase 1 Expansion Data ESMO: Phase 1 Escalation Data SNO: Phase 1 Glioma Data 2 nd line GIST: Pivotal Phase 3 Initiation DCC-3014 Phase 1 Dose Escalation Initiation Phase 1 Dose Escalation Initial Data Rebastinib AACR & ASCO: Trial-in-Progress posters (Investigator sponsored) AACR: Initial Phase 1b Data (Investigator sponsored) Phase 1b Combination Initiation (Company sponsored) Phase 1b Combination with I/O or Chemotherapy Data (Company sponsored) 28
29 NASDAQ:DCPH Shares Outstanding (as of 12/31/17) Cash & Cash Equivalents (as of 12/31/17) 32.6 MM (basic) 37.2 MM (fully-diluted) $197MM Cash to fund operating expenses and capital expenditures into 2H
30 Corporate Summary Well established drug class with significant growth potential Differentiated approach to kinase inhibition Wholly-owned pipeline with three clinical stage assets Kinase Inhibitors: 39 FDA-approved Drugs but Significant Opportunities Remain Drug resistance mutations limit rate and duration of response Low potency and selectivity cause poor tolerability Approved drugs target less than 10% of the 500+ known human kinases Proprietary Kinase Switch Control Inhibitor Platform Broad activity against disease-initiating and drug-resistant mutant kinases Kinase-selective and spectrum-selective profiles Drug discovery engine that fuels long-term growth Strong Pipeline of Tumor-Targeted and Immunokinase Programs DCC-2618: Broad spectrum KIT and PDGFRα inhibitor in first pivotal Phase 3 trial Rebastinib: Highly potent and selective TIE2 inhibitor DCC-3014: Highly selective and potent CSF1R inhibitor 30
31 Addressing Key Mechanisms of Tumor Drug Resistance April 2018 Thank You
DCC-2618, a novel pan-kit and PDGFR
DCC-2618, a novel pan-kit and PDGFRα Kinase switch control inhibitor demonstrates encouraging activity in patients (pts) with Gastrointestinal Stromal Tumors (GIST) N. Somaiah, A. Razak, M. Gordon, F.
More informationEncouraging activity of novel pan-kit and PDGFRα inhibitor DCC-2618 in patients (pts) with gastrointestinal stromal tumor (GIST)
2017 ESMO Proffered Paper Encouraging activity of novel pan-kit and PDGFRα inhibitor DCC-2618 in patients (pts) with gastrointestinal stromal tumor (GIST) F Janku, A Razak, M Gordon, D Flynn, M Kaufman,
More informationUpdate on new agents in Gastrointestinal Tumor (GIST)
Update on new agents in Gastrointestinal Tumor (GIST) Albiruni R Abdul Razak Medical Oncology Sarcoma Site Lead Princess Margaret Cancer Centre/Mount Sinai Hospital 21 st October 2017 1 Disclosure Research
More informationINITIAL RESULTS OF PHASE 1 STUDY OF DCC-2618, A BROAD-SPECTRUM KIT AND PDGFR
INITIAL RESULTS OF PHASE 1 STUDY OF DCC-2618, A BROAD-SPECTRUM KIT AND PDGFR INHIBITOR, IN PATIENTS (PTS) WITH GASTROINTESTINAL STROMAL TUMOR (GIST) BY NUMBER OF PRIOR REGIMENS. S George, M Heinrich, P
More informationGIST: imatinib and beyond
GIST: imatinib and beyond Clinical activity of BLU-285 in advanced gastrointestinal stromal tumor (GIST) Michael Heinrich 1, Robin Jones 2, Margaret von Mehren 3, Patrick Schoffski 4, Sebastian Bauer 5,
More informationClinical activity of BLU-285, a highly potent and selective KIT/PDGFRα inhibitor designed to treat gastrointestinal stromal tumor (GIST)
Clinical activity of BLU-285, a highly potent and selective KIT/PDGFRα inhibitor designed to treat gastrointestinal stromal tumor (GIST) Michael Heinrich 1, Robin Jones 2, Margaret von Mehren 3, Patrick
More informationCirculating Tumor DNA in GIST and its Implications on Treatment
Circulating Tumor DNA in GIST and its Implications on Treatment October 2 nd 2017 Dr. Ciara Kelly Assistant Attending Physician Sarcoma Medical Oncology Service Objectives Background Liquid biopsy & ctdna
More informationARIAD Pharmaceuticals, Inc.
ARIAD Pharmaceuticals, Inc. June 8, 2016 David Sachs Non-small cell lung cancer 1 ARIAD clinical trial patient Some of the statements in this presentation constitute forward looking statements under the
More informationAvapritinib is Highly Active and Well-tolerated in Patients With Advanced GIST Driven by a Diverse Variety of Oncogenic Mutations in KIT and PDGFRA
Avapritinib is Highly Active and Well-tolerated in Patients With Advanced GIST Driven by a Diverse Variety of Oncogenic Mutations in KIT and PDGFRA Michael Heinrich, Margaret von Mehren, Robin L. Jones,
More informationBuilding a Leading Oncology Franchise
ASDAQ: MEIP Building a Leading Oncology Franchise 17th Annual eedham Healthcare Conference March 27, 2018 Forward-Looking Statements This presentation contains, and our officers and representatives may
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 4Q 2016 EARNINGS PRESENTATION MARCH 2017 1 Forward-looking statements disclosure This presentation contains
More informationSpectrum Pharmaceuticals
Spectrum Pharmaceuticals Joe Turgeon President and CEO June 2018 Investor Presentation 1 Safe Harbor Statement This presentation contains forward looking statements regarding future events and the future
More informationJuly, ArQule, Inc.
July, 2012 Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to clinical
More informationCorporate Presentation May Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers
Corporate Presentation May 2016 Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers Forward-looking statements / safe harbor This presentation and the accompanying oral commentary contain
More informationBLU-285: A potent and highly selective inhibitor designed to target malignancies driven by KIT and PDGFRα mutations
BLU-285: A potent and highly selective inhibitor designed to target malignancies driven by KIT and PDGFRα mutations Erica Evans Ph.D. New Drugs on the Horizon 2017 AACR Annual Meeting April 2, 2017 Disclosures
More informationNewLink Genetics Corporation
Cantor Fitzgerald 2018 Global Healthcare Conference NewLink Genetics Corporation NASDAQ: NLNK October 3, 2018 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking
More informationLeading the Next Wave of Biotech Breakthroughs
Leading the Next Wave of Biotech Breakthroughs Corporate Extensive corporate assets Platforms Pipeline Partnerships Building a sustainable global business Platform licenses represent a source of non-dilutive
More informationCORPORATE PRESENTATION
CORPORATE PRESENTATION June 2017 FORWARD LOOKING SAFE HARBOR STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationREWRITING CANCER TREATMENT THROUGH EPIGENETIC MEDICINES
REWRITING CANCER TREATMENT THROUGH EPIGENETIC MEDICINES May 18, 2017 Molecularly Defined Solid Tumor Program Update FORWARD-LOOKING STATEMENTS Any statements in this press release about future expectations,
More informationThird Quarter 2018 Financial Results. November 1, 2018
Third Quarter 2018 Financial Results November 1, 2018 Agios Conference Call Participants Prepared Remarks Introduction RENEE LECK, Associate Director, Investor Relations Business Highlights & 2018 Key
More informationCorporate Presentation
Corporate Presentation Leerink Global Healthcare Conference February 14 th -15 th, 2018 C O N F I D E N T I A L a n d P R O P R I E T A R Y Forward Looking Statements / Safe Harbor This presentation contains
More informationLeerink Immuno-Oncology Roundtable Conference
Leerink Immuno-Oncology Roundtable Conference September 28, 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private
More informationTARGET A BETTER NOW FORWARD-LOOKING STATEMENTS NASDAQ: IMGN. Current as of January 2018
NASDAQ: IMGN TARGET A BETTER NOW Current as of January 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward looking statements based on management's current expectations. These statements
More informationA Biopharmaceutical Company Focused on Controlled Immunotherapies and Point-of-Care Solutions
A Biopharmaceutical Company Focused on Controlled Immunotherapies and Point-of-Care Solutions Second Quarter 2017 Company Update and Financial Results July 31, 2017 2 Forward-Looking Statements This presentation
More informationArQule Jefferies Global Healthcare Conference June 2015
ArQule Jefferies Global Healthcare Conference June 2015 1 ArQule Corporate Update Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning
More information2020 Blueprint global business strategy JANUARY 7, 2019
2020 Blueprint global business strategy JANUARY 7, 2019 Forward-looking statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995,
More informationClinical Trials. Phase II Studies. Connective Tissue Oncology Society. Jon Trent, MD, PhD
Clinical Trials Phase II Studies Jon Trent, MD, PhD Associate Professor Dept. of Sarcoma Medical Oncology The University of Texas, M. D. Anderson Cancer Center Connective Tissue Oncology Society GIST Overview
More informationDCC-2618, a pan-kit and PDGFRA switch control inhibitor, achieves proof-of-concept in a first-in-human study
2016 EORTC-NCI-AACR December 1, 2016 DCC-2618, a pan-kit and PDGFRA switch control inhibitor, achieves proof-of-concept in a first-in-human study Filip Janku, Suzanne George, Albi Razak, Michael Gordon,
More informationArQule CorporateUpdate
ArQule April 2015 1 ArQule CorporateUpdate Safe Harbor This presentation and other statements by ArQule may contain forwardlooking statements within the meaning of the Private Securities Litigation Reform
More informationCompany Overview. April Rewriting cancer treatment NASDAQ: EPZM
Company Overview NASDAQ: EPZM Rewriting cancer treatment Forward Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform
More informationIMMUNOMEDICS, INC. November Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases November 2017 Forward-Looking Statements This presentation, in addition to historical information, contains certain
More informationNewLink Genetics Corporation
Stifel Healthcare Conference Presentation NewLink Genetics Corporation NASDAQ: NLNK November 13, 2018 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements
More informationAVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer
FOR IMMEDIATE RELEASE AVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer Study designed to build upon safety profile demonstrated
More information33 rd Annual J.P. Morgan Healthcare Conference. January 2015
33 rd Annual J.P. Morgan Healthcare Conference January 2015 Forward-looking Statements This presentation contains forward-looking statements, which express the current beliefs and expectations of management.
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer June 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results may
More information2016 Year-End Results and Conference Call. March 14, 2017
2016 Year-End Results and Conference Call March 14, 2017 Forward Looking Statement This communication contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform
More informationInvestor Call. May 19, Nasdaq: IMGN
Investor Call May 19, 2017 Nasdaq: IMGN Forward-Looking Statements This presentation includes forward-looking statements based on management's current expectations. These statements include, but are not
More informationAnti-IL-33 (ANB020) Program
Anti-IL-33 (ANB020) Program Phase 2a Peanut Allergy Clinical Trial Interim Data Update March 26 th 2018 NASDAQ: ANAB Safe Harbor Statement This presentation and the accompanying oral presentation contain
More informationOncology Therapeutics without Compromise APRIL 2011
Oncology Therapeutics without Compromise APRIL 2011 Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties, including among other
More informationInvestor Presentation
Investor Presentation June 2017 Joe Turgeon President and Chief Operating Officer Safe Harbor Statement This presentation contains forward-looking statements regarding future events and the future performance
More informationAVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC
FOR IMMEDIATE RELEASE AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC - Tivozanib is the First Agent to Demonstrate Greater than One Year
More informationDawson James Conference
Dawson James Conference October 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV s current expectations regarding
More informationNovel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates
Novel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates Christopher Turner, MD Vice President, Clinical Science 04 November 2016 Uveal Melanoma Celldex Pipeline CANDIDATE INDICATION Preclinical
More informationFull Year 2017 Financial Results. February 14, 2018
Full Year 2017 Financial Results February 14, 2018 Agios Conference Call Participants Prepared Remarks Introduction KENDRA ADAMS, Sr. Director, Investor Relations 2018 Vision & Key Milestones DAVID SCHENKEIN,
More informationCombining HS-110 and anti-pd-1 in NSCLC. September 1, 2015
Combining HS-110 and anti-pd-1 in NSCLC September 1, 2015 Forward Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases, these forward-looking
More informationGenta Incorporated. A Multiproduct Late-Stage Oncology Company
Genta Incorporated A Multiproduct Late-Stage Oncology Company This presentation may contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 3Q 2018 EARNINGS PRESENTATION NOVEMBER 2018 1 Forward-looking statements disclosure This presentation
More informationCalithera Biosciences. January 2019
Calithera Biosciences January 2019 Forward-Looking Statements This presentation and the accompanying oral commentary contain forward looking statements for purposes of the safe harbor provisions of the
More informationCorporate Presentation November Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers
Corporate Presentation November 2015 Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers Forward-looking statements / safe harbor This presentation and the accompanying oral commentary
More informationInarigivir ACHIEVE Trial Results and HBV Clinical Program Update. August 2, 2018
Inarigivir ACHIEVE Trial Results and HBV Clinical Program Update August 2, 2018 FORWARD LOOKING STATEMENT This presentation includes forward-looking statements within the meaning of the Private Securities
More informationARQ 087 Overview. FGFR Inhibitor. March 2017
ARQ 087 Overview FGFR Inhibitor March 2017 Safe Harbor This presentation and other statements by ArQule contain forward-looking statements within the meaning of the Private Securities Litigation Reform
More informationNASDAQ: CYTR FIGHTING CANCER WITH CUTTING EDGE SCIENCE. Corporate Overview. July 2018
NASDAQ: CYTR Corporate Overview July 2018 CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER MATERIALLY
More informationCalithera Biosciences. September 2018
Calithera Biosciences September 2018 Forward-Looking Statements This presentation and the accompanying oral commentary contain forward looking statements for purposes of the safe harbor provisions of the
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer January 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results
More informationADAPTIMMUNE INVESTOR PRESENTATION. August 2016
ADAPTIMMUNE INVESTOR PRESENTATION August 2016 DISCLAIMER This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),
More informationLION. Corporate Presentation June 2016 BIOTECHNOLOGIES. Leadership & Innovation in Oncology
LION BIOTECHNOLOGIES Leadership & Innovation in Oncology Corporate Presentation June 2016 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private
More informationNASDAQ: TGTX. 33 rd Annual JP Morgan Healthcare Conference
NASDAQ: TGTX 33 rd Annual JP Morgan Healthcare Conference January 2015 Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities
More informationCorporate Overview. February 2018 NASDAQ: CYTR
Corporate Overview February 2018 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER
More informationNOVEL CHECKPOINTS IN IMMUNO-ONCOLOGY KIR NKG2A. C5aR. NKp46 HALF-YEAR RESULTS. Tumor antigen KIR3DL2 CD39 MICA/B CD73 SEPTEMBER 18, 2017
NOVEL CHECKPOINTS IN IMMUNO-ONCOLOGY KIR NKG2A NKp46 C5aR Tumor antigen HALF-YEAR RESULTS KIR3DL2 MICA/B CD73 CD39 SEPTEMBER 18, 2017 Page 2 FORWARD LOOKING STATEMENT This document has been prepared by
More informationNew drugs and trials. Andreas Hochhaus
New drugs and trials. Andreas Hochhaus Hadera I Oct 2018 Introduction ABL001 is a potent, specific inhibitor of BCR-ABL1 with a distinct allosteric mechanism of action BCR-ABL1 Protein Binds a distinct
More informationCalithera Biosciences
Calithera Biosciences March 2019 Forward-Looking Statements This presentation and the accompanying oral commentary contain forward looking statements for purposes of the safe harbor provisions of the Private
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Rodman & Renshaw 19 th Annual Global Investment Conference Michael R. Garone, Principal Executive Officer and CFO Forward-Looking
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer March 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward-looking statements. Rexahn's actual results may
More informationCorporate Overview. June 2017 NASDAQ:FPRX
Corporate Overview June 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of
More informationMANIFEST Phase 2 Enhancement / Expansion
MANIFEST Phase 2 Enhancement / Expansion Investor Conference Call Stellar Science, Breakthrough Medicine October 11, 2018 Forward-Looking Statements This presentation contains forward-looking statements
More informationCorporate Overview. June 2018 NASDAQ:FPRX
Corporate Overview June 2018 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics. Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO Forward-Looking Statements This presentation,
More informationCorporate Overview. May 2017 NASDAQ: CYTR
Corporate Overview May 2017 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER MATERIALLY
More informationCorporate Overview. July 2016 NASDAQ: CYTR
Corporate Overview July 2016 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES ASSOCIATED WITH A DEVELOPMENT-STAGE
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics. Jefferies 2015 Global Healthcare Conference Peter P. Pfreundschuh, VP Finance and CFO
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Jefferies 2015 Global Healthcare Conference Peter P. Pfreundschuh, VP Finance and CFO Forward-Looking Statements This
More informationBusiness Update & Financial Results for Q1 2018
Business Update & Financial Results for Q1 2018 May 15, 2018 Disclaimer The statements made in this presentation may include forward-looking statements regarding the future operations of ERYTECH Pharma
More informationMarch Corporate Presentation
March 2017 Corporate Presentation Disclaimer This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements
More information[ NASDAQ: MEIP ] Cantor Fitzgerald Healthcare Conference July 8, 2015
[ NASDAQ: MEIP ] Cantor Fitzgerald Healthcare Conference July 8, 2015 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements. Actual events or
More informationPersonalized Therapeutics The Power of Epigenetics. Company Overview. June 2014
Personalized Therapeutics The Power of Epigenetics Company Overview June 2014 2013 Accomplishments Forward Looking Statements This presentation contains forward-looking statements that involve substantial
More informationFive Prime Therapeutics, Inc. Corporate Overview
Five Prime Therapeutics, Inc. Corporate Overview June 2015 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities
More informationCorporate Presentation: Jefferies Global Healthcare Conference June 7, 2018
Corporate Presentation: Jefferies Global Healthcare Conference June 7, 2018 2018 CytomX Therapeutics, Inc. 1 Forward Looking Statements Special Note Regarding Forward-Looking Statements This presentation
More informationQ Financial Update November 6, 2018 NASDAQ:FPRX
Q3 2018 Financial Update November 6, 2018 NASDAQ:FPRX 2 Forward-Looking Statements Disclaimer Forward-looking statements contained in this presentation include statements regarding (i) the timing of initiation,
More informationCorporate Presentation October 2018 Nasdaq: ADXS
Innovations in Immuno-Oncology Corporate Presentation October 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements
More informationCorporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC
Corporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC Forward-Looking Statements To the extent that statements contained in this presentation are not descriptions of historical facts
More informationNeedham Healthcare Conference. April 4, 2017
Needham Healthcare Conference April 4, 2017 Forward Looking Statements This presentation and various remarks we make during this presentation contain forward-looking statements within the meaning of The
More informationCorporate Presentation: 2018 Wedbush PacGrow Healthcare Conference August 14, 2018
Corporate Presentation: 2018 Wedbush PacGrow Healthcare Conference August 14, 2018 2018 CytomX Therapeutics, Inc. 1 Forward Looking Statements Special Note Regarding Forward-Looking Statements This presentation
More informationCelyad s CAR-T NKR-2 Program. Conference Call Presentation Wednesday, December 7 th :00pm CET / 8:00am EST
Celyad s CAR-T NKR-2 Program Conference Call Presentation Wednesday, December 7 th 2016 2:00pm CET / 8:00am EST Forward Looking Statements In addition to historical facts or statements of current condition,
More informationBuilding Shareholder Value
Building Shareholder Value June 4, 2014 Jefferies Healthcare Conference Tim Clackson, Ph.D. Hans Loland P r e s i d e n t o f R & D, C h i e f S c i e n t i f i c O f f i c e r with wife Cynthia A R I
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer September 2013 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results
More informationSunesis Pharmaceuticals Reports Second Quarter 2011 Financial Results
Investor and Media Inquiries: David Pitts Argot Partners 212-600-1902 Eric Bjerkholt Sunesis Pharmaceuticals Inc. 650-266-3717 Sunesis Pharmaceuticals Reports Second Quarter 2011 Financial Results SOUTH
More informationMOLOGEN AG. Pioneering Immune Therapy. Annual Results Analysts Call March 25, 2014
Pioneering Immune Therapy Annual Results 2013 Analysts Call March 25, 2014 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future or future developments,
More informationOMP-305B83: A Novel, Potent DLL4 & VEGF Targeting Bispecific Antibody for the Treatment Of Solid Tumors
OMP-305B83: A Novel, Potent DLL4 & VEGF Targeting Bispecific Antibody for the Treatment Of Solid Tumors Jakob Dupont MD MA CMO, SVP: OncoMed Pharmaceuticals Adjunct Clinical Faculty: Stanford University
More informationLehman Brothers Eighth Annual Global Healthcare Conference March 30, 2005 Bruce A. Peacock President and Chief Executive Officer
Lehman Brothers Eighth Annual Global Healthcare Conference March 30, 2005 Bruce A. Peacock President and Chief Executive Officer 2005 Adolor Corporation. All rights reserved. Safe Harbor Statement This
More informationEGFR Mutation-Positive Acquired Resistance: Dominance of T790M
Treatment of EGFR Mutation-Positive Acquired Resistance: T790M+ or T790M- H. Jack West, MD Swedish Cancer Institute, Seattle, WA EGFR Mutation-Positive Acquired Resistance: Dominance of T790M Yu, Clin
More informationRegorafenib from Bayer Submitted to Health Authorities Seeking Approval in Second-Line Treatment of Liver Cancer
News Release Not intended for U.S. and UK Media Bayer AG Communications, Government Relations & Corporate Brand 51368 Leverkusen Germany Tel. +49 214 30-0 www.news.bayer.com Regorafenib from Bayer Submitted
More information[ NASDAQ: MEIP ] August 2014
[ NASDAQ: MEIP ] August 2014 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements. Actual events or results may differ materially from those
More informationRob Ross, MD. Infinity Pharmaceuticals March 9 th, 2011
Heat Shock Protein 90 (Hsp90) Inhibition as a Potential Novel Approach to the Treatment of Patients with ALK Mutated Non-small Cell Lung Cancer (NSCLC) Rob Ross, MD Infinity Pharmaceuticals March 9 th,
More informationTargeting and Treating Cancer
Targeting and Treating Cancer Mark R. Baker, Chief Executive Officer Jefferies Healthcare Conference June 2015 Disclosure Notice This presentation may contain projections and other forward-looking statements
More informationInducing Tumor-Specific Ischemic Necrosis to Enhance the Efficacy of Checkpoint Inhibitors and Chemotherapy
Inducing Tumor-Specific Ischemic Necrosis to Enhance the Efficacy of Checkpoint Inhibitors and Chemotherapy Company Overview, September 2018 Safe Harbor Statement This presentation contains forward-looking
More informationNational Bank 8th Annual Quebec Conference TSX: IMV. May 30, IMV Inc. All rights reserved.
National Bank 8th Annual Quebec Conference TSX: IMV May 30, 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV Inc.
More informationMore cancer patients are being treated with immunotherapy, but
Bristol-Myers Squibb and Five Prime Present Phase 1a/1b Data Evaluating Cabiralizumab (anti-csf-1 receptor antibody) with Opdivo (nivolumab) in Patients with Advanced Solid Tumors PRINCETON, N.J. & SOUTH
More informationCorporate Presentation September Nasdaq: ADXS
Corporate Presentation September 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements regarding the ability and
More information